<?xml version="1.0" encoding="UTF-8"?>
<p>Oseltamivir (
 <xref ref-type="fig" rid="jcm-09-02084-f010">Figure 10</xref>), a neuraminidase inhibitor, has been specifically developed for treating the influenza virus infection [
 <xref rid="B108-jcm-09-02084" ref-type="bibr">108</xref>]. Being structurally designed based on DANA (2,3-dehydro-2-deoxy-N-acetylneuraminic acid), oseltamivir contains a cyclohexene ring with two different substituents compared with DANA; a C4 amino group and a bulky hydrophobic pentyl ether side chain [
 <xref rid="B121-jcm-09-02084" ref-type="bibr">121</xref>]. Oseltamivir is administered as a phosphate prodrug, which is converted by hepatic esterases to the active carboxylate form [
 <xref rid="B122-jcm-09-02084" ref-type="bibr">122</xref>].
</p>
